ArticleNature biomedical engineering2024
Antibody-displaying extracellular vesicles for targeted cancer therapy.
Article in Nature biomedical engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed.
- Bioengineering strategies for improving the immunogenicity of mRNA vaccines.Signal transduction and targeted therapy · 2026Review
- Systemic health impact of cancer-associated extracellular vesicles and particles.Nature reviews. Cancer · 2026Review
- Bioengineered Extracellular Vesicles Mitigate Neuroinflammation by Neutralizing Pneumolysin and Delaying Disease Onset in Experimental Pneumococcal Meningitis.Journal of extracellular vesicles · 2026Article
- Review
- Exosomes as Emerging Therapeutic and Diagnostic Platforms: Biological Functions, Clinical Applications, and Translational Challenges.International journal of molecular sciences · 2026Review
- Extracellular-Vesicle-Associated Nucleic Acids in the Diagnosis and Treatment of Respiratory Diseases: A Narrative Review.Pharmaceutics · 2026Review
- Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies.Molecular cancer · 2026Review
- Targeted extracellular vesicle-photoimmunotherapy remodels stromal-immune microenvironment to boost chemo-immunotherapy in preclinical models.Cell reports. Medicine · 2026Article
- Green nanomedicine for cancer therapy.Chinese medical journal · 2026Review
- Empowering Extracellular Vesicle Wound Therapy via Local Drug Delivery Systems: Mechanistic Insights and Advanced Stimuli-Responsive Strategies.Gels (Basel, Switzerland) · 2026Review
- Tissue derived extracellular vesicles advance from disease mechanisms to clinical application.Discover nano · 2026Review
- Advances in delivery technologies-powered cancer vaccines.Bioactive materials · 2026Review
- The Dual Roles of Extracellular Vesicle Subtypes in Regulating Traumatic Brain Injury.International journal of molecular sciences · 2026Review
- Cell-Specific Extracellular Vesicles Targeting Strategies for Immune Modulation in Inflammatory Diseases.Pharmaceutics · 2026Review
- Stage-Specific Molecular Cargo of Schwann Cell-Derived Extracellular Vesicles is Associated With Peripheral Nerve Repair.Journal of extracellular biology · 2026Article
- Unlocking the potential of extracellular vesicles in cancer diagnosis and therapy: a comprehensive bibliometric study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Engineered extracellular vesicles for combinatorial cancer therapy and imaging.Acta pharmaceutica Sinica. B · 2026Review
- Endogenous Engineering Reprograms Extracellular Vesicles for Enhanced Therapeutic Function.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Advancements in extracellular vesicle research.Extracellular vesicle · 2026Article
- Engineering challenges and translational opportunities in emerging gene delivery platforms.Nature biomedical engineering · 2026Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Extracellular vesicles (EVs) function as natural delivery vectors and mediators of biological signals across tissues. Here, by leveraging these functionalities, we show that EVs decorated with an antibody-binding moiety specific for the fragment crystallizable (Fc) domain can be used as a modular delivery system for targeted cancer therapy. The Fc-EVs can be decorated with different types of immunoglobulin G antibody and thus be targeted to virtually any tissue of interest. Following optimization of the engineered EVs by screening Fc-binding and EV-sorting moieties, we show the targeting of EVs to cancer cells displaying the human epidermal receptor 2 or the programmed-death ligand 1, as well as lower tumour burden and extended survival of mice with subcutaneous melanoma tumours when systemically injected with EVs displaying an antibody for the programmed-death ligand 1 and loaded with the chemotherapeutic doxorubicin. EVs with Fc-binding domains may be adapted to display other Fc-fused proteins, bispecific antibodies and antibody-drug conjugates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.